The Medicines Company: Angiomax(R) / Angiox(R) (bivalirudin) Significantly Improved Net Outcomes in Heart Attack Patients

WASHINGTON--(BUSINESS WIRE)--In a landmark global trial of heart attack patients undergoing angioplasty, the anti-clotting agent Angiomax® (bivalirudin) resulted in superior clinical outcomes and fewer cardiac deaths compared to a more complex treatment regimen. These findings from the HORIZONS AMI1 trial were presented at a late-breaking session of the 19th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium sponsored by the Cardiovascular Research Foundation. Angiomax is available in Europe as Angiox®.

MORE ON THIS TOPIC